EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

Breast Cancer: Targets and Therapy

ISSN 1179-1314 · Informa UK Limited

Latest articles

  1. Adjuvant Trastuzumab Emtansine or Trastuzumab in Initially HER2-Positive Breast Cancer with Residual IHC 0–2+: A Retrospective Multicenter Cohort

    Serdar İleri, Mehmet Sıddık Dilek, Cahit Uçar, Eyyüp Çavdar, Fatma Keskin Uzundere, Ayberk Bayramgil, Oğuzhan Selvi, Sercan Olcar, Hilal Karakaş, İsmail Bayrakçı, Ali Kaan Güren, Nazım Can Demircan, Meltem Baykara, Esma Bayrak Arıstak, Erdem Kölemen, Devrim Çabuk, Esmanur Kaplan Tüzün, İsmail Ertürk, Deniz Can Güven, Murat Bardakci, Vahap Özkan, Murat Arcagök, Sezai Tunç, Oğur Karhan, Mahsum Ozan, Zuhat Urakçı

    Published: 2026-11DOI: 10.2147/bctt.s659921

Volumes

2026 · 1322025 · 1042024 · 762023 · 792022 · 412021 · 582020 · 282019 · 272018 · 282017 · 622016 · 272015 · 372014 · 202013 · 122012 · 222011 · 172010 · 92009 · 4

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.